Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy
Myotonic dystrophy is an autosomal-dominant disorder. Its congenital type is the most severe form, with respiratory failure that can be a life-threatening event after birth. There are no antenatal treatments that can improve neonatal outcomes of myotonic dystrophy. We treated a fetus with congenital...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2019/4290145 |
id |
doaj-78d7ab85e81241409233d9ca9a22c5bf |
---|---|
record_format |
Article |
spelling |
doaj-78d7ab85e81241409233d9ca9a22c5bf2020-11-25T00:02:27ZengHindawi LimitedCase Reports in Obstetrics and Gynecology2090-66842090-66922019-01-01201910.1155/2019/42901454290145Antenatal Indomethacin Treatment for Congenital Myotonic DystrophyKyohei Yamaguchi0Hiroaki Tanaka1Fumi H. Furuhashi2Kayo Tanaka3Eiji Kondo4Tomoaki Ikeda5Department of Obstetrics and Gynecology, Mie University, Mie, JapanDepartment of Obstetrics and Gynecology, Mie University, Mie, JapanDepartment of Obstetrics and Gynecology, Mie University, Mie, JapanDepartment of Obstetrics and Gynecology, Mie University, Mie, JapanDepartment of Obstetrics and Gynecology, Mie University, Mie, JapanDepartment of Obstetrics and Gynecology, Mie University, Mie, JapanMyotonic dystrophy is an autosomal-dominant disorder. Its congenital type is the most severe form, with respiratory failure that can be a life-threatening event after birth. There are no antenatal treatments that can improve neonatal outcomes of myotonic dystrophy. We treated a fetus with congenital myotonic dystrophy by administering indomethacin to the 31-year-old Japanese mother affected by myotonic dystrophy and polyhydramnios. We observed increased fetal breathing movement and a reduction of the amniotic fluid volume. The baby was born at 37 weeks and discharged from the neonatal intensive care unit with a favorable outcome. Indomethacin treatment is likely to improve fetal lung function and to control the amniotic fluid volume. This report emphasizes the importance of further investigations regarding the optimal management of congenital myotonic dystrophy.http://dx.doi.org/10.1155/2019/4290145 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kyohei Yamaguchi Hiroaki Tanaka Fumi H. Furuhashi Kayo Tanaka Eiji Kondo Tomoaki Ikeda |
spellingShingle |
Kyohei Yamaguchi Hiroaki Tanaka Fumi H. Furuhashi Kayo Tanaka Eiji Kondo Tomoaki Ikeda Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy Case Reports in Obstetrics and Gynecology |
author_facet |
Kyohei Yamaguchi Hiroaki Tanaka Fumi H. Furuhashi Kayo Tanaka Eiji Kondo Tomoaki Ikeda |
author_sort |
Kyohei Yamaguchi |
title |
Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy |
title_short |
Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy |
title_full |
Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy |
title_fullStr |
Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy |
title_full_unstemmed |
Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy |
title_sort |
antenatal indomethacin treatment for congenital myotonic dystrophy |
publisher |
Hindawi Limited |
series |
Case Reports in Obstetrics and Gynecology |
issn |
2090-6684 2090-6692 |
publishDate |
2019-01-01 |
description |
Myotonic dystrophy is an autosomal-dominant disorder. Its congenital type is the most severe form, with respiratory failure that can be a life-threatening event after birth. There are no antenatal treatments that can improve neonatal outcomes of myotonic dystrophy. We treated a fetus with congenital myotonic dystrophy by administering indomethacin to the 31-year-old Japanese mother affected by myotonic dystrophy and polyhydramnios. We observed increased fetal breathing movement and a reduction of the amniotic fluid volume. The baby was born at 37 weeks and discharged from the neonatal intensive care unit with a favorable outcome. Indomethacin treatment is likely to improve fetal lung function and to control the amniotic fluid volume. This report emphasizes the importance of further investigations regarding the optimal management of congenital myotonic dystrophy. |
url |
http://dx.doi.org/10.1155/2019/4290145 |
work_keys_str_mv |
AT kyoheiyamaguchi antenatalindomethacintreatmentforcongenitalmyotonicdystrophy AT hiroakitanaka antenatalindomethacintreatmentforcongenitalmyotonicdystrophy AT fumihfuruhashi antenatalindomethacintreatmentforcongenitalmyotonicdystrophy AT kayotanaka antenatalindomethacintreatmentforcongenitalmyotonicdystrophy AT eijikondo antenatalindomethacintreatmentforcongenitalmyotonicdystrophy AT tomoakiikeda antenatalindomethacintreatmentforcongenitalmyotonicdystrophy |
_version_ |
1725437641153839104 |